Yamanouchi restructures and simplifies its existing agreements with Pfizer that allow both companies to work independently in the development and marketing of their own products in Japan. Furthermore, the companies have concurrently entered into a new agreement to co-develop and co-promote Pfizer’s COX-2 inhibitors in Japan.